A new trial found an arthritis drug, tocilizumab, may ease depression linked to inflammation — and a simple blood test could predict who benefits.

Adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease ...

Dr Denis Poddubnyy discusses data from the AXIS study that inform his approach to diagnosing axial psoriatic arthritis.

Eli Lilly and Company announced new phase 3b data, showing that combining ixekizumab (Taltz) with tirzepatide (Zepbound) produced improved and durable efficacy at 1 year in adults with psoriatic ...

How erythema nodosum can be misdiagnosed – in this case as cellulitis – and what clues can help you to spot it promptly and ...

Officials are warning of the spread of another multistate outbreak of deadly bacteria that has sickened 22 people and ...

German study focused on cases referred to rheumatologists ...

These refreshing smoothies feature gut-healthy ingredients like chia seeds and apples for a flavorful sip perfect for fall.

Results from phase 3b trials show a greater benefit at 52 weeks for patients with psoriasis or psoriatic arthritis treated with ixekizumab plus tirzepatide vs ixekizumab alone.

Current European and UK guidance incorporates comorbidity assessment and, where appropriate, communication between ...

LUND, SE / ACCESS Newswire / September 7, 2026 / AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as ...

Pfizer Korea said Friday that its tumor necrosis factor (TNF) inhibitor Enbrel (etanercept) has gained national health ...